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Abstract
Triple negative breast cancers (TNBC) are genetically characterized by aberrations in TP53 and a 
low rate of activating point mutations in common oncogenes, rendering it challenging in applying 
targeted therapies. We performed whole exome sequencing (WES) and RNAseq to identify 
somatic genetic alterations in mouse models of TNBCs driven by loss of Trp53 alone or in 
combination with Brca1. Amplifications or translocations that resulted in elevated oncoprotein 
expressions or oncoprotein-containing fusions, respectively, as well as frame-shift mutations of 
tumor suppressors were identified in approximately 50% of the tumors evaluated. While the 
spectrum of sporadic genetic alterations was diverse, the majority had in common the ability to 
activate the MAPK/PI3K pathways. Importantly, we demonstrated that approved or experimental 
drugs efficiently induce tumor regression specifically in tumors harboring somatic aberrations of 
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the drug target. Our study suggests that the combination of WES and RNAseq on human TNBC 
will lead to the identification of actionable therapeutic targets for precision medicine guided 
TNBC treatment.
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Introduction
Targeted therapies for breast cancer treatment using estrogen receptor (ER)-antagonists, 
monoclonal antibodies or small molecules directed against HER2 for tumors expressing 
these cognate targets have resulted in great improvement in patient survival in ER+, PR+ and 
HER2 amplified patient populations (1–3). By contrast, there are no similar specific targeted 
therapies available for triple negative breast cancer (TNBC), which is defined by the absence 
of ER, progesterone receptor (PR) and HER2. This disease occurs more commonly in 
younger women and in women of African and Hispanic descent, and patients are at higher 
risk of local or distant recurrence and worse prognosis when compared to other breast cancer 
subtypes (4). Despite significant efforts, little progress has been made, and chemotherapy 
remains the standard of care for TNBC patients.
TNBC patients exhibit highly variable responses to chemotherapy, which is likely linked to 
the significant molecular differences observed among these tumors (4). Recent profiling of 
the tumor transcriptomes have highlighted the heterogeneity in TNBC (5,6), and 
transcriptional profiling allowed the classification of TNBC into discrete subgroups, each 
with distinct expression profiles and, importantly, clinical implications (5,7). Large-scale 
whole exome sequencing (WES) and whole genome sequencing projects further 
demonstrated the molecular basis for TNBC tumor heterogeneity, revealing a diverse range 
and number of mutations, chromosomal number variations and translocations (7–9). While 
over 80% of TNBC patients harbor point mutations or deletions in the TP53 locus and a 
smaller subset have point mutations in genes controlling the PI3K pathway (PTEN, PIK3CA 
and INPP4B), gain of function point mutations that are common in other cancers such as 
those found in BRAF, KRAS and EGFR are rare events in TNBCs (8–11). Several of these 
oncogenic drivers are potentially targetable using small molecules that are either FDA-
approved or currently undergoing clinical evaluation. However, the low frequency of each 
oncogenic mutation in TNBC patients precludes the broad usage of any single targeted agent 
in this patient population. Rather, these data provide a rationale for pursuing a precision 
medicine approach to identify potential drivers, and to tailor treatment regimens based upon 
the somatic alteration spectrum specific to each patient’s tumor.
Several issues confound applying precision medicine approaches to TNBCs. Most trials do 
not require genomic profiling on biopsies at the time of enrollment, rendering correlations 
between clinical responses and genetic aberrations difficult to establish. In recent years, 
patient-derived-xenografts (PDXs) have been used to test personalized medicine approaches 
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in treating patient-derived breast cancers (12). However, these models use immuno-
compromised mice and their clinical applicability remains unclear.
Here, we took a complementary approach to establish genetically engineered mouse models 
(GEMMs) harboring breast-specific Tp53 deletion with or without concomitant Brca1 
deletion. We carried out whole exome sequencing (WES) and RNAseq on the tumors that 
these TNBC models developed and confirmed that they faithfully recapitulated features of 
human TNBC disease. We were able to identify putative driver aberrations, including 
chromosomal amplifications and deletions, chromosomal translocations, mutations and 
proto-oncogene overexpression specific to individual tumors. Interestingly, although 
different tumors harbor different genetic aberrations, many of these share the ability of 
enhancing MAPK and PI3K pathway activation. In addition, when a particular tumor was 
treated with frontline therapeutic drugs targeting predicted oncogenic drivers specific to that 
tumor, sustained tumor remission was achieved. These data further support the tumor-
promoting functions of these genetic events and support the paradigm of genomics-guided 
treatment in TNBC. Our results suggest that the combination of whole exome sequencing 
and RNAseq on human TNBC can reveal genetic aberrations that would be missed by 
conventional approaches that evaluate mutational events in panels of known oncogene. 
Importantly, our results suggest that this approach can significantly extend the use of 
approved or experimental drugs for TNBC patients who progress on standard of care 
treatments.
Results
Establishment of Brca1-deficient and Brca1-WT TNBC mouse models
The majority of TNBC tumors possess TP53 mutations and approximately 15% of patients 
carry germ-line BRCA1 mutations (4). We generated two cohorts of mice to model both 
BRCA1-germline mutation carriers and sporadic TNBCs: K14cre; p53flox/flox; Brca1flox/flox, 
defined as Brca1-deficient cohort; and K14cre; p53flox/flox; Brca1 wt/wt, defined as Brca1-
WT cohort. (Figure S1A). The majority of tumors developed from these mouse models were 
ER-, PR- and HER2-negative, with histopathological characteristics reminiscent of human 
TNBCs (Figure 1A, and S1B). To further investigate whether these mouse models resembled 
human TNBC, we performed RNAseq on RNAs isolated from tumors and from age-matched 
normal mammary glands to analyze their transcriptional profiles. Both AIMS and PAM50 
classifier algorithms (13,14), as well as unsupervised hierarchical clustering were used to 
identify the intrinsic subtypes of these mouse tumors. AIMS assigned almost all mouse 
tumors with high probability into basal-like breast cancer tumor subtypes, while all three 
normal mammary glands were assigned to the “normal-like” subtype (Figure 1B). Similarly, 
PAM50 assigned most of the tumors to the basal-like breast cancer subtype, which is the 
subtype most commonly associated with TNBC (15) (Figure S1C). In addition, unsupervised 
hierarchical clustering of the mouse tumors with RNAseq expression profiles from TCGA 
breast cancer samples on the 138 shared genes between mouse and human revealed that the 
mouse tumors segregated with human TNBCs, and not with other breast cancer subtypes 
(Figure S1D, Supplemental Table 1). Therefore, both immunohistological analysis and 
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transcriptional profiling indicated that these mouse tumors, developed on a Tp53-deficient 
background with or without Brca1, provide reasonable models for human TNBC.
RNAseq and WES revealed heterogeneous aberrations in murine TNBC
To identify spontaneous genetic aberrations that potentially are oncogenic drivers of these 
tumors, we performed WES on tumor DNA and matched germ-line DNA. We observed low 
somatic mutation rates; an average of 30 somatic mutations (and 17 non-synonymous 
mutations) were found in the coding exons per tumor, ranging from 0 to 104 mutations 
across our set (Figure 1C and supplementary Table 2). Among all non-synonymous 
mutations, we only identified Kras Q61H and Hras Q61K as potential oncogenic driver 
mutation in two of the primary tumors. Both mutations have been observed in human tumors 
and have been shown to drive transformation in cell lines ((16,17) and http://
cancer.sanger.ac.uk/cosmic/mutation/overview?id=554). Although other mutations were 
identified, they were not at hotspots in human oncogenes and their oncogenic potential 
remains to be determined (Figure S1E). We compared the mouse tumor mutational 
signatures to the 21 mutation signatures identified in human cancers (18), and found that 
Brca1-deficient tumors were most similar to signature 3, which is associated with BRCA1/2 
mutations in human breast cancer (Figure 1D)(8). We also found that the mutation signature 
for Brca1-WT tumors were most similar to signature 17, which has an unknown etiology 
(Figure 1D and S1F).
Next, we analyzed somatic copy number alterations (CNAs) to investigate chromosomal 
gains and losses in these murine tumors. Overall, the CNA profiles exhibited marked 
variability among the tumors (Figure 1E and Supplementary Table 3). Consistent with 
human breast cancer (19), the Brca1-deficient subgroup exhibited more amplifications and 
deletions than the Brca1-WT subgroup (Figure S1G), supporting that loss of Brca1 
contributes to genomic instability. The most recurrent events were focal amplifications on 
chromosome 6 centered on the Met locus and amplifications on chromosome 9 centered on 
the Yap1 locus (Figure 1F and Fig. S1H). Amplification of the Met gene was observed in 10 
out of the 32 Brca1-WT primary tumors but none in Brca1-Deletion tumors. Amplifications 
in the Yap1 gene were found in 8/32 Brca1-WT and 1/30 Brca1-Deletion tumors. We also 
observed recurrent chromosomal gain at the Myc locus on chromosome 15, and deletion of 
the Rb locus within a broad region on chromosomal 14 (Figure S1H). In addition to these 
recurrent amplification events, we identified sporadic high focal amplification on 
chromosome 7 that includes the Fgfr2 locus, on chromosome 11 that includes Egfr locus, 
and a bi-allelic deletion on chromosome 19 that includes the Pten locus in one tumor (Figure 
1G and S1I).
We integrated WES data with RNAseq data to investigate whether CNA alterations lead to 
changes in the expression levels of the affected genes. Among the recurrent amplifications, 7 
of the 10 Met amplified tumors indeed showed increased Met transcript levels, and 6 of the 9 
Yap1 amplifications resulted in elevated mRNA expression (Figure 1F). In addition, we 
found that tumor #1 with the Fgfr2 amplification expressed significantly higher level of 
Fgfr2 mRNA compared to other tumors that were CNA-neutral at this locus. The tumor with 
a focal amplification of Efgr was among the ones expressing the highest Egfr mRNA levels. 
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The tumor harboring a bi-allelic Pten deletion expressed the lowest Pten mRNA levels 
among all tumors (Figure 1G). It has been shown that over-expression of MET (20,21), 
EGFR (22–24), YAP1 (25–27), or FGFR2 (28,29), as well as deletion of PTEN (30,31) 
contribute to TNBC tumorigenesis, and our data suggest that through combined RNAseq and 
WES data analyses, potential oncogenic drivers of TNBC tumors can be identified.
Chromosomal rearrangements in primary and transplanted tumors
Analysis of RNAseq data also revealed the presence of chromosomal translocation events, 
which varied from tumor to tumor (Figure S2A) and a subset of these rearrangements 
resulted in mRNA fusions (Figures 2A and 2B). Several of the fusions involved genes 
encoding proto-oncogenic protein kinases (Fig. S2B and Supplementary Table 4). Three 
different Ffgr2-fusions were observed, Fgfr2-Dnm3 (Dynamin 3) in tumor #1 and Fgfr2-
Tns1 (Tensin 1) in tumor #6, and Fgfr2-Zmynd8 where the distal portion of the Fgfr2 gene 
was replaced by the translocation partners, potentially generating fusion proteins (Figure 
2C) with intact kinase domains. Proteins generated from these Fgfr2-fusion transcripts share 
the same domain architecture as FGFR2-fusions identified in human breast cancer (32,33). 
Notably, in tumor #1 where Fgfr2-Dnm3 translocation was observed, the chromosomal 
region encoding Fgfr2 was highly amplified, while in tumor #6 with an Fgfr2-Tns1 fusion, 
the chromosomal region covering Fgfr2 exhibited some gain in copy number (Figure S1I). 
Translocations involving the Raf family kinases were also detected, including a Dlg1 (disc 
large 1)-B-Raf fusion in tumor #3, Dhx9 (DEAH-Box Helicase 9)-Raf1 fusion in tumor #5, 
and Rpl32 (Ribosomal Protein L32)-Raf1 fusion in tumor #25. In all cases, the fusion 
proteins had an intact RAF kinase domain while the RAF N-terminal regulatory domain was 
replaced by the fusion partners, similar to BRAF-fusions identified in metastatic breast 
cancer (34) and other BRAF- and RAF1-fusions found in different human tumor types (35–
37) (Figure 2C and Figure S2C).
We validated the presence of fusion transcripts in tumors harboring Fgfr2- and Raf1-fusions 
by RT-PCR and traditional Sanger Sequencing using primer pairs that either match the input 
RNAs (match primers) or not (mismatch primers). PCR products of expected sizes were 
observed for matching RNA/primers, but not for mismatch RNA/primers (Figure 2D). When 
RT-PCR products were gel extracted and sequenced by traditional Sanger sequencing, the 
junctions were confirmed (Figure 2E, and S2D–F).
Thus, through combined WES and RNAseq analyses, we detected spontaneous 
chromosomal amplifications of Met, Yap1, Egfr and Fgfr2, a bi-allelic deletion of Pten, 
oncogenic mutations in Kras and Hras, as well as sporadic fusions of Fgfr2-Dnm3, Fgfr2-
Tns1, Fgfr2-Zmydn8, Dhx9-Raf1, and Rpl32-Raf1and Dlg1-Braf in distinct tumors.
Aberrant genetic events possess oncogenic activity by enhancing MAPK and/or PI3K 
pathway activations
We next investigated whether the fused transcripts resulted in functional fusion proteins. We 
detected the Fgfr2-Dnm3 fusion protein in tumor #1 at the predicted size of 99 kDa using 
antibodies recognizing the N-terminus of Fgfr2 and the C-terminus of Dnm3. Importantly, 
the presence of Fgfr2-Dnm3 coincided with elevated phosphorylation of the Fgfr2 substrate 
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Frs2 (Figure 3A and Figure S3A for sample key). To confirm the presence of Fgfr2-Tns1 
fusion proteins, we immunoprecipitated Fgfr2 and subjected proteins at the predicted 
molecular mass (265 kDal) for mass spectrometry, and identified peptides from both Fgfr2 
and Tns1 (Figure 3B and Figure S3B for peptide sequences matching Fgfr2 or Tns1). We 
also confirmed the presence of the Dhx9-Raf1 fusion protein in tumor #5 at the expected 
molecular weight (51 kDa) (Figure 3C), and this tumor exhibited elevated activation of the 
MAPK signaling pathway as measured by ERK phosphorylation, compared to tumors that 
lacked Raf fusions (Figure 3C, and Figure S3C).
The tumor with high Met mRNA expression had elevated tyrosine-phosphorylated Met 
compared to tumors that lacked Met overexpression (Fig. 3D and Fig. S3D). The tumor with 
bi-allelic deletion of Pten (#17) exhibited low levels of Pten protein and elevated PI3K-
pathway activation detected by high levels of phospho-AKT and high levels of 
phosphorylation of the AKT substrate, PRAS40 (Figure 3E and S3E).
Fgfr2-, Braf- and Raf1-Fusion kinases exhibit enhanced MAPK and/or PI3K pathway 
activation and oncogenic activity
To evaluate the oncogenic potential of the novel fusion proteins, we cloned HA-tagged 
Fgfr2-Dnm3, Dhx9-Raf1 and Rpl32-Raf1 into pBabe-puro and generated stable NIH3T3 
cells and carried out signaling analyses and soft-agar colony formation assays. FGFR2 
fusions, similar to the ones we observed in mice albeit with different translocation partners, 
have been reported in human breast and thyroid cancers (32,33) and we included one of 
these fusions, FGFR2-CCDC6 (coiled-coil domain containing 6, Figure S4A) in our assays.
Expression of the fusion proteins was confirmed by blotting for the HA-tag, Fgfr2, and 
Raf1, (Figure S4B and S4C). We found that expression of Fgfr2-Dnm3 and FGFR2-CCDC6 
resulted in FGFR2 activation detected by phospho-Tyr653/654 of FGFR2, and substrate 
phosphorylation detected by phospho-FRS2 at Tyr436. As a consequence, downstream PI3K 
activation was enhanced as measured by phospho-AKT (Figure 4A and Figure S4B, S4C). 
Moreover, both Fgfr2-Dnm3 and FGFR2-CCDC6 induced anchorage-independent growth of 
NIH3T3 cells in soft agar (Figure 4B). To understand the mechanisms for enhanced pathway 
activation, we transiently expressed epitope-tagged FGFR2-fusions in HEK293T cells and 
assayed for ligand-independent oligomerization/dimerization by co-immunoprecipitation in 
serum-free condition, and we found both FGFR2-CCDC6 and Ffgr2-Dnms3 undergo homo-
oligomerization in the absence of FGF but fail to oligomerize with endogenous FGFR2s 
(Figure 4C). These results are consistent with a model in which the C-terminal fusion 
partner (CCDC6 and Dnms3) mediates the homo-multimerization.
By contrast, expression of Dhx9-Raf1 and Rpl32-Raf1 stimulated MAPK pathway activation 
with minimal impact on PI3K pathway activation in NIH3T3 cells (Figure 4D), and this also 
resulted in the significantly increased capacity to form colonies in soft agar (Figure 4E).
We also analyzed the effects of these fusion proteins in immortalized human mammary 
epithelial cells (HMECs). Consistent with the results obtained in NIH3T3 cells, Fgfr2-Dnm3 
expression increased both MAPK and PI3K signaling in epithelial cells (Figure S4D). 
Surprisingly, Dhx9-Raf1 expression in epithelial cells also enhanced activation of the PI3K 
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pathway (Figure S4D). Previous studies have shown autocrine production of various growth 
factors contribute to Raf1-mediated PI3K activation in mammary epithelial cells (38–41), 
which may explain the signaling differences observed between NIH3T3 cells and HMECs. 
In addition, expression of the fusion proteins resulted in increased proliferation of HMECs 
(Figure 4F). cMet-overexpression resulted in spontaneous cMET phosphorylation in the 
absence of growth factors and enhanced pAKT and pERK levels (Figure 4G), as well as 
increased cell proliferation (Figure S4E).
Altogether, our results identify a likely driver event in approximately 50% of the 72 tumors 
evaluated (Figure 4H). Our data show that the majority of the genetic alterations we 
identified have in common the ability to enhance activation of MAPK and/or PI3K 
signaling.
Tumors harboring Fgfr2 fusion proteins are responsive to FGFR2-inhibition in vivo, 
resulting in complete tumor regression
Next, we asked whether the murine TNBC tumors that spontaneously acquired the Fgfr2 or 
Raf1 translocations would respond to drugs that target these protein kinases. To this end, we 
transplanted mouse TNBC tumors with identifiable potential genetic drivers in cohorts of 
nude mice, and each mouse received a designated treatment regimen (Figure S5A). Targeted 
agents were selected based on (i) high specificity and high competence indicated by low 
IC50, (ii) good in vivo bioavailability with low in vivo dosing, and (iii) approved for cancer 
therapy or currently in phase II or III clinical trials. Based on these criteria, NVP-BGJ398 
was chosen as an FGFR-inhibitor (Figure S5B), Trametinib (GSK1120212) as a MEK-
inhibitor (Figure S6A), and Crizotinib as a MET-inhibitor (Figure S6D) for in vivo 
treatments.
For tumor #1, which is Brca1-deficient with a spontaneous Fgfr2-Dnm3 translocation, we 
evaluated the efficacy of FGFR-inhibitor BGJ398 alone, or in combination with Olaparib (a 
PARP-inhibitor approved for BRCA1 mutant cancers) (Figure 5A), anticipating that tumors 
may become resistant on monotherapy. We also included Crizotinib in this trial, reasoning 
that Met is not the driver in this particular tumor and it should therefore not respond to this 
treatment. We determined that the dose of BGJ398 needed to suppress Frs2 phosphorylation 
was 30mg/kg (Figure 5B), which is estimated to be equivalent to a human dose of 2.4mg/kg 
(42), and the dose of Olaparib had previously been reported (43). We did not observe general 
toxicity over prolonged treatment (Figure 5C). At this dose, BGJ398 alone was sufficient to 
induce complete tumor regression (Figure 5D). This outcome was a significant improvement 
compared to a pan-PI3K inhibitor BKM120 treatment, which only resulted in slower rate of 
tumor progression (Figure S5C). Importantly, Crizotinib had no effect on the growth of 
tumor #1 (Figure 5D), although it was capable of delaying tumor progression when Met 
levels are elevated (Figure 6F), supporting the notion that the choice of treatment should be 
based on the genetics of the tumor. At early time points (up to 33 days), BGJ398 and the 
combination of BGJ398 and Olaparib were equally effective in inducing tumor remission. 
However, three of six tumors on BGJ398 monotherapy developed resistance, and on average 
at day 43 (day 36, 47 and 57) tumors relapsed to the initial volume (Figure 5E). By contrast, 
tumors treated with BGJ398 and Olaparib combination therapy did not relapse when the 
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experiment ended, and all tumors reached complete response (CR) (Figure 5E). Using a 
second PARP-inhibitor BioMarine BMN673 (44) in combination with BGJ398, no tumor 
relapse was observed for up to 80 days (Figure S5D). Our data suggest that spontaneous 
Fgfr2-Dnm3 fusions can drive tumorigenesis in the breast.
For tumor #6, which is Brca1-WT with a spontaneous Fgfr2-Tns1 translocation, we 
compared BGJ398 alone to the PI3K-inhibitor BKM120 (Figure S5E) since Brca1-WT 
murine tumors are less sensitive to PARP-inhibition relative to PI3K-inhibition (Figure 
S5E). We treated tumor-bearing mice with BGJ398, BKM120 alone, or in combination 
(Figure S5F). We observed that BKM120 treatment resulted in stable disease (SD), although 
with general toxicity (Figure S5G). However, BGJ398 alone induced tumor regression, and 
the combination of both drugs caused fast and complete tumor remission until no tumor 
tissue could be detected (Figure 5F). The combination did not cause further toxicity beyond 
what was elicited by BKM120 alone (Figure S5G). Our data show that spontaneous tumors 
with Fgfr2 aberrations are responsive to FGFR2-inhibitor treatments, suggesting complete 
tumor regression can be achieved when genetic alterations of each tumor are carefully 
considered.
Tumors with Raf1-fusion or overexpressing Met responded to specific inhibitors targeting 
these pathways
Since MEK inhibitors have been shown to effectively treat human tumors driven by mutated 
Raf family members, we treated tumor # 5 that expresses the Dhx9-Raf1fusion protein with 
the MEK inhibitor Trametinib (GSK1120212). A 3mg/kg/day dose of Trametinib was 
effective in blocking Erk phosphorylation (Figure 6A). Mice implanted with tumor #5 were 
given Trametinib as either a single agent, or in combination with Olaparib since tumor #5 is 
a Brca1-deficient tumor (Figure 6B). Either single agent or combination therapy did not 
cause general toxicity at the doses used (Figure S6B). Consistent with our hypothesis, 
Trametinib alone significantly delayed tumor growth, with an initial phase of stable disease, 
which transitioned to progressive disease after 14 days (Figure S6C). Olaparib alone initially 
did not halt tumor growth, but slowly resulted in tumor regression. When mice were treated 
with a combination of both the MEK and PARP inhibitors, tumor #5 completely regressed 
without relapse upon extended treatment for up to 50 days till the experiment ended (Figure 
6C). It is also important to note that when treated with the FGFR-inhibitor BGJ398, tumor 
#5 (Dhx9-Raf1 fusion) failed to respond (Figure 6C and S6C), further supporting the 
importance of identifying and suppressing specific oncogenic activities in specific patient 
subpopulations.
RNAseq revealed that a group of tumors derived from the same primary tumor (Tumor #2)
(Figure 1F) exhibited approximately a 30-fold increase in cMet mRNA levels compared to 
other tumors evaluated, despite no amplification in the Met locus. Since Met overexpression 
enhances spontaneous MET activation in cells, we evaluated the effect of Crizotinib, an 
inhibitor of both MET and ALK tyrosine kinases, on the growth of these tumors. At 
50mg/kg, Crizotinib completely blocked cMET phosphorylation in tumors, as well as 
downstream AKT, ERK and S6 phosphorylation (Figure 6D) without general toxicity 
(Figure S6D). While overall survival for mice receiving control treatment is only 8 days, 
Liu et al. Page 8
Cancer Discov. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Crizotinib treatment delays tumor progression and tripled survival to 24 days (Figure 6E). 
Combining Crizotinib with BKM120 (Figure 6F) achieved stable disease in this particularly 
aggressive tumor (Figure 6E). The effect of Crizotinib on the tumor was probably a 
consequence of inhibiting MET since, as discussed above, Crizotinib had little effect on 
Tumor #1 (Fig. 5D), which does not overexpress MET.
The results presented in Figures 5 and 6 indicate that either complete tumor regression or 
stable disease can be achieved, using monotherapy or combination therapy with inhibitors 
that target the pathways that are affected by the genetic aberrations specific to individual 
tumors. These in vivo treatment results not only confirm the functional importance of these 
genetic events in tumor development, but also provide evidence that individualized treatment 
design based on genomic information can lead to significantly improved outcomes.
Human TNBCs harbor a broad range of targetable genetic alterations
Our data show that despite the use of highly inbred mice and common initiating events 
(breast-specific deletion of Tp53 alone or deletion of both Tp53 and Brca1), tumors took 
diverse evolutionary pathways to become TNBC. Yet the majority of the tumors converged 
on genetic alterations enhancing MAPK and PI3K signaling pathways. Therefore, we 
analyzed TCGA human breast cancer data to investigate genetic alterations known to 
enhance MAPK and/or PI3K pathway activation.
We first interrogated 82 tumors in the TCGA database that were annotated as TNBC. 
Specifically, we searched for mutations and amplifications in KRAS, BRAF and RAF1 
genes; mutation, amplification and overexpression in genes encoding for receptor tyrosine 
kinases (RTKs); as well as genes involved in the PI3K pathway. We found that 
approximately 90% of all TNBCs have at least one such genetic aberration (Figure 7A and 
Figure S7A). To determine whether this high prevalence is specific to TNBC, or is generally 
true for all breast cancer, we investigated the TCGA breast cancer database (816 cases) and 
the METABRIC database (Molecular Taxonomy of Breast Cancer International Consortium, 
2509 cases), and found that 72% and 56% of breast tumor samples show at least one of these 
changes, with the majority of the tumors displaying two or more alterations (Figure 7A and 
S7B). The result from this search suggests that while genetic changes leading to potential 
MAPK/PI3K activation are common, such alterations may be particularly important for 
TNBC development.
Since mouse tumors with spontaneous Fgfr-signaling pathway activation are sensitive to the 
FGFR-inhibitor BGJ398, we were interested in further investigating genetic alterations of 
the FGFR-family of receptor tyrosine kinases and their ligands. In addition to translocations, 
mutations and focal amplifications can also activate the FGFR family (32,33,45,46). 
Therefore, we also analyzed the COSMIC databases as well as TCGA and METABRIC 
databases to identify mutations for FGFR and FGF family members. We found that 
chromosomal amplifications of the FGFR1, FGFR2 and FGF3/4/19 loci (Figure 7B and 
S7C) resulted in increased mRNA levels of FGFR1, FGFR2 and FGF4/19 (Figure 7C and 
S7D). Overall, 34% and 26% of all breast cancer patients showed FGFR1, FGFR2 and/or 
FGF3 mutation/amplification/overexpression in TCGA and METABRIC, respectively 
(Figure S7E). Mutations in FGFR1 are rare, but 1.2% of all breast cancer patients have 
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FGFR2 mutations, including known activating mutations such as S252W, N549K and 
K659E (Figure 7D).
These data indicate that in both genetically engineered mouse models and in human patients, 
the genetic alterations in TNBC are quite diverse but converge on a relatively limited 
number of ways to activate the MAPK and/or PI3K pathways (Figure 7E).
Discussion
In this work, we generated two GEMM models that are Tp53-deficient, with or without 
Brca1-deficiency, and carried out whole exome sequencing and RNAseq on these 
spontaneously developed tumors. We found that these TNBC mouse models recapitulate 
many aspects of human TNBC, including the overall transcriptional profile, mutational 
burden and signature as well as heterogeneous CNAs. We identified spontaneous genetic 
aberrations that were likely drivers of the evolution of these tumors. These genetic 
aberrations include both recurrent chromosomal amplifications of the Met and Yap1 loci, 
and sporadic amplification at the Fgfr2 and Egfr loci, a bi-allelic deletion of Pten in 
individual tumors. In addition, spontaneous Fgfr2-Dnm3, Fgfr2-Tns1, Fgfr2-Zymnd8, 
Dhx9-Raf, Rpl32-Raf1 and Dlg1-BRaf translocations that generate overexpressed, and/or 
constitutively active protein kinases were also discovered as oncogenic drivers. Point 
mutations of known oncogenes were rare; however, we identified tumors with activating 
mutations in Kras and Hras. Our results also showed that the majority of these genetic 
aberrations have in common the ability to enhance MAPK and PI3K pathway signaling. 
Next we asked to what extent these pathways are activated by genetic alterations known to 
occur in human breast cancer. We searched TCGA breast cancer database for KRAS, BRAF, 
and RAF1 mutations and amplifications, RTK gene mutations, amplifications and 
overexpressions, YAP1 amplification/gain/overexpression, PIK3CA mutations and 
amplifications, as well as PTEN and INPP4B deletions, all of which can potentially activate 
the MAPK and/or PI3K pathways. More than 60% of breast tumors bear at least one of these 
aberrations, while over 90% of the TNBC subgroup of breast cancers exhibit these genetic 
lesions, suggesting the importance of MAPK and PI3K signaling pathway activation in 
TNBC tumorigenesis.
Through combined WES and RNAseq analyses, we identified potential oncogenic drivers in 
approximately 50% of tumors against which frontline drugs are also available 
(Supplementary Table 5). It is worth noting that almost all of these genetic driver fusions 
would not be detected by conventional targeted sequencing approaches that only investigate 
mutational events in panels of known oncogenes. The mutational burden of murine tumors is 
relatively low, averaging 30 somatic mutations per tumor with 17 non-synonymous 
mutations. These numbers are comparatively lower than those of human TNBC, which 
average 127 somatic mutations per tumor with 107 being non-synonymous (TCGA data 
analysis and (9)), reflecting cross-species/age differences. Nevertheless, we do observe 
similar mutational patterns between Brca1-deficient murine tumors and Brca1-mutant 
human breast tumors (Figure 1).
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We found recurrent Met and Yap amplification in 20% and 22% of primary mouse tumors 
investigated, as well as individual tumors showing increased mRNA levels without 
chromosomal amplification. Overall, approximately 25% of the primary tumors show 
amplification/gain/overexpression of Met or Yap (Figure 1 and S1). Our data are consistent 
with human TCGA data, where 27% or 29% of TNBC patients show amplification/gain/
overexpression of MET or YAP, supporting the importance of these genetic events in TNBC 
development (20,21,27). Current data also point to the role of YAP1 in activation of the 
PI3K/MAPK pathway via increased PIK3CB, HRAS or GAB2 expression, or increased IRS 
phosphorylation in diverse types of tumors (47–50). We also observed recurrent c-Myc 
amplification and Rb1 deletion in the mouse tumors, although both tend to occur in broader 
chromosomal regions. These data are consistent with a report by Holstege in mouse tumors 
(19), and also CBIO Portal analyses of human TNBC (http://www.cbioportal.org/index.do?
session_id=59edd065498e5df2e29710eb&show_samples=false&). In addition to these 
recurrent CNAs, sporadic amplifications and deletions that affect cancer-related genes were 
identified, including high amplification of Fgfr2 and Egfr loci, and deep deletion of the Pten 
locus, as well as shallow amplification of the Cdk6, Aurka, and Jun loci, and deletion of the 
Nf1 loci (Supplementary Table # 3). Our data suggest that although normal mouse and 
human chromosomes bear major differences in their architectures, mouse tumors developed 
over 7-12 months exhibited similar changes in their cognate regions to human tumor 
genomes.
In addition to chromosomal amplifications and deletions at known oncogenic loci, 
chromosomal translocations were found to be the oncogenic drivers in a subset of the murine 
tumors. Interestingly, although mutational burden is low in human breast cancer, ranking 
20th among 30 different cancer types (18), the chromosomal rearrangement frequency ranks 
among the highest (Figure S7F and data generated based on “TCGA Fusion gene Data 
Portal” http://54.84.12.177/PanCanFusV2/), although the frequency of recurrent 
translocations is low. Traditionally viewed as important oncogenic drivers for hematological 
cancers (51), chromosomal rearrangement events have been identified and increasingly 
recognized as potent drivers in human solid tumors (33,34,36,52–54). Through next 
generation sequencing, a number of gene fusions with low frequency were identified in 
breast cancer patients, including FGFR2, FGFR3, BRAF, NTRK3, and MET (32,33,36,53–
55). We also identified chromosomal translocations involving Fgfr2, Braf and Raf1 that 
resulted in constitutively active fusion kinases in the mouse tumors. We noticed that the 
fusion partners in the mouse tumors are different from those found in the human 
counterparts. However, it has been shown that these kinases tend to fuse with different 
partners in human tumors, while maintaining similar domain architecture. Typically, fusion 
events involving FGFR2 and FGFR3 occur at the C-terminus, replacing the C-terminus of 
FGFRs with different fusion partners that provide the ability of the fused protein to undergo 
spontaneous homo-multimerization (Figure S7G) (33,45,54). Our data confirmed that the 
fusion partner found in mouse tumors has similar functions (Figure 4C). Similarly it is 
commonly observed that a diverse set of genes can fuse with Raf family members, 
generating fusion kinases where the N-terminal regulatory domain of Raf is replaced by the 
fusion partner, resulting in constitutive activation of the Raf family kinases (Figure S7H)
(34–37,53).
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Further evidence for the oncogenic function of a genetic alteration is provided when such 
alterations confer sensitivity to targeted therapy that results in an objective response only in 
patients harboring the genetic alteration. This, in fact, represents the litmus test for the 
precision medicine approach in cancer treatment. We carried out individualized treatment 
studies based on the specific driver(s) present in a particular tumor. This allowed us to 
confirm that these predicted drivers indeed are important for tumor growth in vivo. We show 
that two tumors with Fgfr2 fusions responded to the FGFR inhibitor BGJ398, a tumor with a 
Raf1 fusion responded to the MEK-inhibitor Trametinib and a tumor with overexpressed 
MET responded to the MET inhibitor Crizotinib, verifying that these spontaneous genetic 
aberrations were driving tumor growth in each of the individual tumors. Importantly, the 
tumor with Fgfr2-Dnm3 fusion did not respond to Met inhibition, nor was the FGFR2-
inhibitior BGJ398 effective on the Met overexpressing tumor, highlighting the importance of 
matching therapeutic drugs with oncogenic drivers.
Our study indicates that although the evolutionary courses that lead to breast tumor 
formation in the context of Tp53 deletion, with or without Brca1 deletion, are diverse, they 
have in common the ability to activate the MAPK and/or PI3K pathway. However, targeting 
both PI3K and MAPK pathways resulted in high toxicity and is not a viable option for 
patients. Our study suggests approved drugs or experimental drugs could be effective 
therapies when targeting upstream driver events, which can be identified by combined WES 
and RNAseq efforts.
One such upstream driver event is the FGFR activation. The importance of FGFR pathway 
in tumorigenesis has increasingly been recognized (56,57), and FGFR fusions have been 
found in bladder, thyroid, prostate, lung cancer, glioblastoma and cholangiocarcinomas 
(Figure S7H) (33,45,54). We demonstrated that mouse Fgfr2-Dnm3 and human FGFR2-
CCDC6 fusion kinases share similar oncogenic potential and activation mechanism. Our 
result that the FGFR-inhibitor BGJ398 (58) is effective in treating murine tumors harboring 
Fgfr2-fusions is also consistent with recent data obtained in a cholangiocarcinomas PDX 
model harboring FGFR2-CCDC6 fusion treated with BGJ398 (59). Together these results 
support ongoing clinical trails targeting the FGFR in various cancers (https://
clinicaltrials.gov), and some of which have shown therapeutic benefits. A phase II trial 
evaluating the efficacy of the TKI258 FGFR-inhibitor in patients with or without FGFR2 
mutations showed increased overall survival when mutations are detected (20.2 months with 
mutations vs 9.3 months without) (Clinical Trial # NCT01379534). A recently published 
basket trial targeting patients with potential FGFR pathway activations also found BGJ398 
provided disease control in 37% of patients (49 of 132 patients) who have failed all available 
standard therapies. And for breast cancer patients with FGFR1/2 amplification or mutation, 
BGJ398 alone resulted in stable disease in 31% (10 of 31) patients, although the disease 
eventually progressed on this treatment (60). These data support the potential of FGFR 
inhibitors in cancer treatment, but also highlights their limitation as monotherapy in long-
term disease management.
Similar to available human trials, we found that although tumors harboring FGFR2 fusions 
responded well initially to BGJ398 monotherapy, this response is not sustained and tumors 
relapsed despite continuous treatment (60). Given our success with the FGFR inhibitor 
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BGJ398 as part of combination therapy with PARP inhibitor in treating Brca1-deficient 
tumors, or with BKM120 in treating Brca1-WT tumors, we suggest that including BGJ398 
as part of combination treatment regimens warrants further investigation in patients with 
FGFR family genetic aberrations and either germline or sporadic defects in DNA repair 
pathways.
Fusion kinases involving the RAF family members (B-RAF and RAF1) have been found 
with high frequency in pilocytic astrocytomas(61,62) and at low frequency in 
melanoma(63,64), pancreatic(35), prostate(37), thyroid (65)and metastatic breast 
cancer(34,66). We reasoned that although RAF1-fusions have not been found in human 
TNBC, Dhx9-Raf1 identified in the murine models share the same architecture as fusion-
RAF1s discovered in other tumor types. Therefore, it is important to consider and evaluate 
fusion kinases involving the Raf family members as therapeutic targets in vivo, and identify 
effective treatments for these fusion-containing tumors in breast cancer and beyond. We 
reported here that a TNBC tumor with Raf1-fusion kinase is responsive to Trametinib as a 
single agent, and note that since this tumor was Brca1-deficient the efficacy of Trametinib 
was improved when combined with Olaparib. Our data suggest the potential of treating 
RAF1 fusion containing tumors with MEK inhibitors.
Given that cMet overexpression synergizes with Tp53-loss to induce basal-like breast cancer 
(typically TNBCs) (20,21), and cMet amplification and overexpression correlate with 
TNBC, it is encouraging that the murine tumor with Met overexpression responded to the 
MET-inhibitor Crizotinib either as monotherapy or in combination with the PI3K-inhibitor 
BKM120. This result is consistent with reports that targeting MET in MET-amplified TNBC 
mouse tumors results in an initial complete response (67). Combining MET and PARP 
inhibitor has been shown to suppressed Olaparib-resistant TNBC tumor cell growth in vivo 
(68).
Another potential therapeutic target in TNBC that emerged from this study is YAP1, a 
transcription factor that is normally suppressed by the Hippo tumor suppressor pathway. 
YAP1 collaborates with other transcription factors including TEAD and AP1 to promote 
tumorigenesis and metastasis (26,69,70). In fact, Verteporfin, which inhibits YAP1 and 
TEAD interaction and thus transcriptional activity, has been used in vitro and in vivo 
(49,71). It will be interesting to investigate the efficacy of this approach in our TNBC mouse 
model.
In summary, we have generated mouse models that recapitulate human TNBC. Through 
combined WES and RNAseq, we identified amplifications and fusions of oncogenic drivers 
that would have been missed by evaluating mutations in panels of known oncogenes. We 
investigated the efficacy of this precision medicine approach by treating each tumor as an 
individual patient using frontline drugs targeting specific oncogenic drivers. Our results 
indicate the importance of performing RNAseq and whole exome sequencing on TNBC in 
order to identify the genetic aberrations driving the disease. These data also underscore the 
importance of combination therapy in order to elicit prolonged treatment efficacy. This work 
provides a proof-of-principle evidence for on-going basket trials, NCI-MATCH 
(NCT02465060), My Pathway Trial (NCT02091141) and the European ESMART 
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(NCT02813135), which are designed to match the specific abnormalities with therapeutic 
drugs.
Methods
Endogenous tumor generation
All animal studies were reviewed and approved by the Institutional Animal Care and Use 
Committee (IACUC) at the Beth Israel Deaconess Medical Center. K14cre; Brca1flox/flox; 
Tp53flox/flox mice were obtained from Dr. Jos Jonkers’ lab (Netherlands Cancer Institute).
Orthotopic tumor implantation
Tumor pieces were cut into 2 mm in diameter and inserted into the 4th mammary fat pad of 
8-week old recipient mice via a 0.5cm incision in the skin and the skin was closed with 
VetBond as described (43).
Tumor treatment and tumor measurement
Once tumors reached 8mm in diameter as measured by electrical caliper (Fisher Scientific), 
mice were treated with indicated drugs obtained from MedChemExpress, LLC. For oral 
gavage, 100ul of drug suspension was administrated daily for six consecutive days, followed 
by one drug holiday. Tumor sizes were measured twice a week (length and width), and 
tumor volume was calculated as (3.14*length*width*width/6).
RNA and library preparation
Total RNA was prepared following the protocol for Promega ReliaPrep RNA Tissue 
Miniprep System (Z6111), and RNA integrity and concentration were measured using the 
Agilent 2100 Bioanalyzer (Agilent Technologies). cDNA libraries were prepared from 15–
35 ng RNA starting material (RIN values >6.0), using the TruSeq RNA Sample Preparation 
Kit (Illumina) according to the manufacturer’s instructions, and quality was checked on an 
Agilent 2100 Bioanalyzer (Agilent Technologies). Sequencing was carried out on the HiSeq 
2500 (Illumina) using paired end clustering and 51×2 cycles sequencing.
Genomic DNA and library preparation
Genomic DNA from tumor or liver samples was prepared following the protocol for 
Promega ReliaPrep Tissue DNA Miniprep System (A2051). SureSelect or NimbleGen 
Mouse exome capture kits were used to generate DNA library according to manufacturer’s 
instructions. Sequencing was carried out using HiSeq4000 (Illunima) using paired end 
clustering and 51×2 cycles sequencing. The NCBI BioProject accession number for both 
RNAseq and WES sequences reported in this paper is PRJNA398328.
Sequence Analysis
The quality of the raw FASTQ files was checked with FastQC. RNAseq reads were mapped 
to GRCm38 using STAR and expression levels (FPKMs) quantified using Cufflinks with 
default parameters. WES reads were mapped to GRCm38 using BWA then de-duplicated, 
realigned around indels, and base recalibrated. We classified the mouse tumors into the 
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breast cancer intrinsic subtypes using AIMs and PAM50 classifiers after conversion of 
mouse gene symbols to human Entrez gene IDs and human gene symbols, respectively. 
PAM50 centroids were re-computed using RNAseq expression profiles from TCGA breast 
cancer data and their associated, published PAM50 classification as gold standard. Gene 
fusions were called using FusionCatcher and filtered for false positives.
Mutation and copy number analysis
Somatic mutations were identified upon removing any mutations found in any tail, liver or 
normal mammary control samples, in mouse dbSNP, or with insufficient coverage in the 
control samples. Mutations were annotated with SnpEff. Copy number variants were called 
using CNVkit after removing low-quality reads. Sample-specific thresholds were computed 
to call amplifications and deletions.
Cell culture
Primary human mammary epithelial cells (HMECs) were isolated and immortalized on 
passage 3 as described (72) upon informed consent (DFHCC-IRB legacy 04-405). Cells 
were maintained in MEGM medium (Lonza, Walkersville, MD) and used within 10 
passages. NIH3T3 cells were obtained from and authenticated by ATCC in 2014 and 
cultured in DMEM medium with 10% fetal calf serum and were used within 10 passages. 
Retrovirus and lentivirus preparation and infection were carried out as described (73) using 
Lipofectamine 2000 (ThermoFisher).
Protein lysis, western Blots, immunoprecipitation (IP), silver staining and mass 
spectrometry (MS)
Tumors and cells were lysed in RIPA lysis buffer with protease inhibitors and phosphatase 
inhibitors (Sigma), and protein quantifications were performed using BCA Protein Assay 
(Pierce). Equal amount of total proteins were used for Western blots or IP, and gels were 
stained using Pierce Silver Staining kit (# 24612), while MS was carried out as described 
(74). See supplementary material and methods for detailed antibody information.
Cell Proliferation and soft agar formation assay
For cell proliferation assay, 1500 cells were plated in 96-well plates and measured with 
CellTiter-Glo (Promega, G7572). For soft agar colony assay, 10,000 cells were resuspended 
in 0.4% agar (SeaPlaque low melting agar, Lonza) in cell growth medium and plated on 
0.8% agar in 6-well plates. Medium was changed every week and after 3 weeks, cells were 
fixed and stained in 0.005% Crystal Violet in 20% Methanol in PBS.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
Using combined whole exome sequencing and RNAseq analyses, we identified sporadic 
oncogenic events in TNBC mouse models that share the capacity to activate the MAPK 
and/or PI3K pathways. Our data support a treatment tailored to the genetics of individual 
tumors that parallels the approaches being investigated in the ongoing NCI-MATCH, My 
Pathway Trial and the ESMART clinical trials.
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Figure 1. 
Establishment of TNBC mouse models that recapitulate many aspects of human TNBC 
including heterogeneous genomic alterations A) H&E and IHC staining of ER, PR and 
HER2 for tumors developed in GEMM models. B) Transcriptional classification using 
AIMS reveals endogenous tumors developed in the mouse models are most similar to basal-
like breast cancer. C) Endogenous mouse tumors show a range of mutations. D) Mutational 
signature for each Brca1 genotype. The six boxes show the relative frequency of each of the 
six substitution types, and within each box are the 16 substitution contexts depending on the 
5′ and 3′ base pair context. E) Global CNA profile shows heterogeneous amplifications and 
deletions among different tumors. F) Recurrent amplification at the Met and Yap1 loci in the 
mouse tumors and their corresponding mRNA levels. Amplified samples are in red. G) 
Individual tumors with Egfr or Fgfr2 amplification express higher mRNA levels (expressed 
as Fragments Per Kilobase Million or PRKM) of Egfr or Fgfr2, respectively, while a tumor 
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with Pten deletion shows low Pten transcript level. Arrows indicating amplified or deleted 
samples are in red.
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Figure 2. 
Next generation sequencing of the endogenous TNBC tumors from GEMM models 
identifies multiple chromosomal rearrangement events. A) An overall view of fusion events 
in mouse breast tumors. B) Representative Circos plots show different numbers and pattern 
in chromosomal translocations among different tumors. C) Domain structure of Fgfr2-, 
Braf- and Raf1-fusion kinases. D) RT-PCR and E) Sanger sequencing confirming the 
presence of Fgfr2-Dnm3, Fgfr2-Tns1, and Dhx9-Raf1 fusion transcripts in each of the 
spontaneous tumors.
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Figure 3. 
Western blotting confirming the presence of fusion proteins in tumor lysates and showing 
increased signaling pathway activation in respective tumors. A) Tumor #1 series express 
Fgfr2-Dnm3 fusion proteins at expected molecular weight (left). At the same molecular 
weight, its fusion partner Dnm3 is also detected. Fgfr2-Dnm3 expression coincides with 
enhanced FRS2 phosphorylation. B) Detection of Fgfr2-Tns1 in tumor #6 by mass 
spectrometry (MS) upon Fgfr2-immunoprecipitation. Short gray blocks show the locations 
of peptides identified by MS. C) Tumor #3 series express Dhx9-Raf1 fusion proteins at the 
expected molecular weight with increased pERK signals. D) Tumor #2 express high level of 
cMet at the protein levels, which coincide with increased Met phosphorylation. E) Tumor 
#17 that harbors bi-allelic Pten deletion expresses undetectable Pten at the protein levels, 
and high Akt- and Pras40-phosphorylation.
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Figure 4. 
Kinase fusions function as oncogenic drivers via enhanced activation of the MAPK and/or 
PI3K pathways. A) Expression of FGFR2-CCDC6 or Fgfr2-Dnm3 results in increased 
Fgfr2, Frs2 and downstream Akt phosphorylation in NIH3T3 cells. B) FGFR2-CCDC6 and 
Fgfr2-Dnm3 confer soft-agar colony formation capacity in NIH3T3 cells. C) Both Fgfr2-
Dnm3 and FGFR2-CCDC6 dimerize/oligomerize in a ligand-independent manner with 
fusion kinases but not with endogenous Fgfr2. D) Expressing of Dhx9-Raf1 or Rpl32-Raf1 
fusion kinases significantly enhances the MAPK pathway in NIH3T3 cells. E) Dhx9-Raf1 
and Rpl32-Raf1 fusion kinases confer soft-agar colony formation ability. F) Expression of 
FGFR2-CCDC6, Fgfr2-Dnm3, Dhx9-Raf1 or Rpl32-Raf1 increases HMEC proliferation. G) 
MET overexpression in HMECs induces spontaneous MET phosphorylation. H) Potential 
oncogenic driver events identified through combined WES and RNAseq analyses.
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Figure 5. 
Targeting Fgfr2-fusion containing tumors with the FGFR-inhibitor BGJ398 results in 
complete response. A) Treatment designs for tumor #1 that is Brca1-deficient and harbors 
Fgfr2-Dnm3 translocation. B) In vivo dosing of BGJ398 at 30mg/kg achieves target 
inhibition measured by pFrs2 and pErk levels. C) BGJ398 alone, or in combination with 
Olaparib does not cause general toxicity in nude mice. D) BGJ398 alone or in combination 
with Olaparib results in complete tumor remission. E) Spider plot showing tumor responses 
to each treatment over long duration. F) BGJ398 alone results in slow tumor regression 
while BKM120 and BGJ398 causes fast tumor remission.
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Figure 6. 
Targeting Dhx9-Raf1 and cMet with MEK- and MET-inhibitor, respectively, result in tumor 
regression or delayed progression. A) MEK inhibitor Trametinib (GSK1120212) achieves 
target inhibition at 3mg/kg. B) Treatment designs for Brca1-deficient tumor #5 harboring 
Dhx9-Raf1 translocation. C) Trametinib alone delays tumor progression while Trametinib 
and Olaparib result in complete tumor remission. D) At 50mg/kg, Crizotinib inhibits MET 
phosphorylation and downstream signaling pathway activation. E) Targeting Met-
overexpressing endogenous tumor with MET-inhibitor delays tumor progression, and 
combination therapy results in stable disease. F) Treatment designs for tumor #2 that is 
Brca1-WT and overexpresses cMET.
Liu et al. Page 28
Cancer Discov. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 7. 
Multiple, different genetic aberrations lead to common elevated MAPK and/or PI3K 
pathway activation in human breast cancer patients. A) Frequent genetic alterations that are 
known to activate the MAPK and/or PI3K pathways in TNBC patients (CbioPortal TCGA 
data). B) Frequency of amplification at the FGFR1, FGFR2 and FGF19 loci. C) Genomic 
amplification of FGFR1 and FGFR2 results in increased mRNA expression levels. D) 
Location and frequency of mutations found in FGFR1 and FGFR2 in breast cancer. E) A 
model showing multiple genetic aberrations in TNBC leading to the activation of MAPK 
and/or PI3K pathways.
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